CEBPZ and acute myeloid leukemia: However, as predicted by our in vitro models (see also Figure 3), one patient with CBF AML harboring the less common KIT D816Y mutation demonstrated sensitivity with an IC50 for reduction of viable cells of approximately 1300 nM.